Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Lidor, YJ, Xu, FJ, Martínez-Maza, O, Olt, GJ, Marks, JR, Berchuck, A, Ramakrishnan, S, Berek, JS, and Bast, RC. "Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells." Exp Cell Res 207, no. 2 (August 1993): 332-339.

Full Text

Xu, FJ, Yu, YH, Daly, L, DeSombre, K, Anselmino, L, Hass, GM, Berchuck, A, Soper, JT, Clarke-Pearson, DL, and Boyer, C. "OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures." J Clin Oncol 11, no. 8 (August 1993): 1506-1510.

Full Text

McKenzie, SJ, DeSombre, KA, Bast, BS, Hollis, DR, Whitaker, RS, Berchuck, A, Boyer, CM, and Bast, RC. "Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer." Cancer 71, no. 12 (June 15, 1993): 3942-3946.

Scholars@Duke

Jordan, PA, Kerns, BJ, Pence, JC, Kohler, MF, Bast, RC, Kinney, RB, and Berchuck, A. "Determination of proliferation index in advanced ovarian cancer using quantitative image analysis." Am J Clin Pathol 99, no. 6 (June 1993): 736-740.

Scholars@Duke

Kohler, MF, Kerns, BJ, Humphrey, PA, Marks, JR, Bast, RC, and Berchuck, A. "Mutation and overexpression of p53 in early-stage epithelial ovarian cancer." Obstet Gynecol 81, no. 5 ( Pt 1) (May 1993): 643-650.

Scholars@Duke

KOHLER, MF, KERNS, BJM, HUMPHREY, PA, MARKS, JR, BAST, RC, and BERCHUCK, A. "MUTATION AND OVEREXPRESSION OF P53 IN EARLY-STAGE EPITHELIAL OVARIAN-CANCER." OBSTETRICS AND GYNECOLOGY 81, no. 5 (May 1993): 643-650.

Scholars@Duke

Sasaki, H, Nishii, H, Takahashi, H, Tada, A, Furusato, M, Terashima, Y, Siegal, GP, Parker, SL, Kohler, MF, and Berchuck, A. "Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma." Cancer Res 53, no. 8 (April 15, 1993): 1906-1910.

Scholars@Duke

Wu, S, Boyer, CM, Whitaker, RS, Berchuck, A, Wiener, JR, Weinberg, JB, and Bast, RC. "Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression." Cancer Res 53, no. 8 (April 15, 1993): 1939-1944.

Scholars@Duke

Clarke-Pearson, DL, Synan, IS, Dodge, R, Soper, JT, Berchuck, A, and Coleman, RE. "A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery." Am J Obstet Gynecol 168, no. 4 (April 1993): 1146-1153.

Scholars@Duke

Jacobs, IJ, Smith, SA, Wiseman, RW, Futreal, PA, Harrington, T, Osborne, RJ, Leech, V, Molyneux, A, Berchuck, A, and Ponder, BA. "A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus." Cancer Res 53, no. 6 (March 15, 1993): 1218-1221.

Scholars@Duke

Pages